Company / Total Debt
Abbott Laboratories Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$12.9B
FY2025
5-year range
$12.9B / $18.1B
FY2021-FY2025
Trend
-8.5%
vs FY2024
Sector context
#10 of 100
Health Care
What the data says
Among 100 Health Care companies, Abbott Laboratories is in the bottom 10% for total debt. Total Debt has declined for 5 consecutive years, from $18.5B in FY2020 to $12.9B in FY2025.
Based on SEC 10-K filings.
$12.9B in FY2025 with a 5-year CAGR of -6.9%. Top quartile in the Health Care sector.
Improved from $14.7B to $12.9B over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -8.3%
- 5-Year CAGR
- -6.9%
- 10-Year CAGR
- -
Sector benchmark
Bottom 10% in Health CareTop 90% of 100This company $12.9B Sector average $4.6B
▼
+184.0% above sector average
Key checks
Key Insights
- Abbott Laboratories's total debt has declined for 5 consecutive years.
- 5-year CAGR of -6.9%, indicating a declining trend.
- In FY2025, total debt decreased 8.5% year-over-year.
- Ranks #10 out of 100 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $12.9B | -8.5% |
| FY2024 | $14.1B | -3.8% |
| FY2023 | $14.7B | -12.5% |
| FY2022 | $16.8B | -7.1% |
| FY2021 | $18.1B | -2.6% |
| FY2020 | $18.5B | +3.3% |
| FY2019 | $17.9B | -7.4% |
| FY2018 | $19.4B | -30.1% |
| FY2017 | $27.7B | +34.0% |
| FY2016 | $20.7B | +252.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026